Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7363
-0.0297 (-3.88%)
At close: Aug 10, 2026, 4:00 PM EDT
0.7363
0.00 (0.00%)
After-hours: Aug 10, 2026, 5:03 PM EDT
Longeveron Revenue
Longeveron had revenue of $398.00K in the quarter ending March 31, 2026, with 4.46% growth. This brings the company's revenue in the last twelve months to $1.22M, down -45.35% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%.
Revenue (ttm)
$1.22M
Revenue Growth
-45.35%
P/S Ratio
19.90
Revenue / Employee
$32,000
Employees
38
Market Cap
24.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Allarity Therapeutics | 345.00K |
LGVN News
- 7 days ago - Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 - GlobeNewsWire
- 18 days ago - Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors - GlobeNewsWire
- 4 weeks ago - Longeveron presents positive laromestrocel data in Alzheimer’s disease - TheFly
- 4 weeks ago - Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Longeveron appoints Marie Washburn CFO - TheFly
- 5 weeks ago - Longeveron® Appoints Marie Washburn as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Longeveron Transcript: AGM 2026 - Transcripts
- 7 weeks ago - New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire